ImmuPharma Dirección

Dirección controles de criterios 4/4

El CEO de ImmuPharma's es Tim McCarthy , nombrado en Jul 2021, tiene una permanencia de 2.75 años. compensación anual total es £106.50K, compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.36% de las acciones de la empresa, por valor de €37.16K. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 9.7 años, respectivamente.

Información clave

Tim McCarthy

Chief Executive Officer (CEO)

UK£106.5k

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	2.8yrs
Participación del CEO	0.4%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	9.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Tim McCarthy en comparación con los beneficios de ImmuPharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	-UK£3m
Mar 31 2023	n/a	n/a	-UK£3m
Dec 31 2022	UK£107k	UK£107k	-UK£4m
Sep 30 2022	n/a	n/a	-UK£5m
Jun 30 2022	n/a	n/a	-UK£6m
Mar 31 2022	n/a	n/a	-UK£7m
Dec 31 2021	UK£575k	UK£287k	-UK£8m
Sep 30 2021	n/a	n/a	-UK£8m
Jun 30 2021	n/a	n/a	-UK£8m
Mar 31 2021	n/a	n/a	-UK£7m
Dec 31 2020	UK£260k	n/a	-UK£7m
Sep 30 2020	n/a	n/a	-UK£6m
Jun 30 2020	n/a	n/a	-UK£5m
Mar 31 2020	n/a	n/a	-UK£6m
Dec 31 2019	UK£260k	n/a	-UK£6m
Sep 30 2019	n/a	n/a	-UK£7m
Jun 30 2019	n/a	n/a	-UK£7m
Mar 31 2019	n/a	n/a	-UK£7m
Dec 31 2018	UK£260k	n/a	-UK£7m
Sep 30 2018	n/a	n/a	-UK£7m
Jun 30 2018	n/a	n/a	-UK£7m
Mar 31 2018	n/a	n/a	-UK£7m
Dec 31 2017	UK£260k	n/a	-UK£6m

Compensación vs. Mercado: La compensación total de Tim($USD133.27K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD406.04K).

Compensación vs. Ingresos: La compensación de Tim ha sido consistente con los resultados de la empresa en el último año.

CEO

Tim McCarthy (67 yo)

2.8yrs

Permanencia

UK£106,500

Compensación

Mr. Timothy Paul McCarthy, XIV, also known as Tim, MBA, FCCA, is Independent Non-Executive Chairman at 4basebio PLC. He co-founded Alizyme PLC in 1995. Mr. McCarthy serves as the Chairman of ImmuPharma plc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Timothy McCarthy	Chairman & CEO	2.8yrs	UK£106.50k	0.36% £ 37.5k
Timothy Franklin	COO & Director	4.3yrs	UK£92.50k	0.13% £ 13.2k
Lisa Baderoon	Head of Investor Relations & Non Executive Director	12.3yrs	UK£48.00k	0.38% £ 39.9k
Jean-Marie Geiger	Head of Clinical Development	no data	sin datos	sin datos
Laura Mauran-Ambrosino	Chief Scientific Officer of ImmuPharma Biotech	1.7yrs	sin datos	sin datos
Lara Sucheston-Campbell	Head of Clinical & Medical Affairs	1.3yrs	sin datos	sin datos
Sébastien R. Goudreau	CEO of ImmuPharma Biotec & Director	1.7yrs	sin datos	0.036% £ 3.8k

2.3yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 25I se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Timothy McCarthy	Chairman & CEO	8.7yrs	UK£106.50k	0.36% £ 37.5k
Timothy Franklin	COO & Director	2.8yrs	UK£92.50k	0.13% £ 13.2k
Lisa Baderoon	Head of Investor Relations & Non Executive Director	2.8yrs	UK£48.00k	0.38% £ 39.9k
Sébastien R. Goudreau	CEO of ImmuPharma Biotec & Director	less than a year	sin datos	0.036% £ 3.8k
Lee Simon	Member of Scientific Advisory Board	10.8yrs	sin datos	sin datos
Vibeke Strand	Member of Scientific Advisory Board	10.8yrs	sin datos	sin datos
David Isenberg	Member of Scientific Advisory Board	10.8yrs	sin datos	sin datos
Daniel Wallace	Member of Scientific Advisory Board	10.8yrs	sin datos	sin datos
Cees Kallenberg	Member of Scientific Advisory Board	10.8yrs	sin datos	sin datos
Laurence Reilly	Senior independent Non-Executive Director	less than a year	sin datos	sin datos

9.8yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de 25I se considera experimentada (9.7 años de antigüedad promedio).

ImmuPharma Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director

No independent directors

ImmuPharma plc Announces Changes to Its Board of Directors

ImmuPharma plc, Annual General Meeting, Jun 30, 2023

ImmuPharma plc, Annual General Meeting, May 26, 2023

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray PanCan-d test in the US market

Recent updates

Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory Director

New minor risk - Financial data availability

Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic Lupuzortm

Immunovia Successfully Completes Discovery Phase of Next-Generation Test Development

No independent directors

ImmuPharma plc Announces Changes to Its Board of Directors

Immunovia to Significantly Restructure to Focus Resources on Its Next-Generation Blood Test for Pancreatic Cancer Detection

New major risk - Market cap size

ImmuPharma plc, Annual General Meeting, Jun 30, 2023

ImmuPharma plc, Annual General Meeting, May 26, 2023

ImmuPharma plc Announces Further Positive Progress in Late-Stage Clinical Program in Patients with Chronic Idiopathic Demyelinating Polyneuropathy

Immunovia Announces Realigning Swedish Operations with Strategic Priorities and Its Focus on the US Commercialization of the IMMray™ PanCan-d test

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray PanCan-d test in the US market

Less than half of directors are independent

ImmuPharma plc to Report Q1, 2023 Results on Apr 25, 2023

ImmuPharma plc Appoints Ward Williams Limited as Company Secretary

First half 2022 earnings released: EPS: UK£0 (vs UK£0.015 loss in 1H 2021)

ImmuPharma PLC Provides Update on Lupuzor

ImmuPharma plc, Annual General Meeting, Jun 28, 2022

Full year 2021 earnings released: UK£0.032 loss per share (vs UK£0.034 loss in FY 2020)

ImmuPharma plc Provides Update on Lupuzor Progress to Phase 3 with Avion

No independent directors

ImmuPharma plc Provides Positive Data from Lupuzor/P140 Pharmacokinetic Study

ImmuPharma plc Provides an Update on the Lupuzor™ Pharmacokinetic Study, as Part of the New Optimized International Phase 3 Trial of Lupuzor™ in Lupus Patients

First half 2021 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in 1H 2020)

Less than half of directors are independent

Independent Non-Executive Director Stéphane Robert Méry has left the company

Senior Independent Non-Executive Director Franco Di Muzio has left the company

Co-Founder, President, Chief Scientific Officer & Director D. Henri Zimmer has left the company

Full year 2020 earnings released: UK£0.034 loss per share (vs UK£0.04 loss in FY 2019)

ImmuPharma plc Appoints Ewa Flynn as Company Secretary

ImmuPharma plc Announces Guidance on Forthcoming International Phase 3 Trial of Lupuzor™ in Lupus Patients

ImmuPharma plc Announces Update on Submission to the FDA

ImmuPharma plc Announces Completion of Analysis from the IMMray and PanCan-d Verification Study

First half earnings released

Immunovia Announces Positive Results from the IMMray Pancan-D Verification Study

ImmuPharma plc announced that it expects to receive £2.35 million in funding from L1 Capital Pty. Limited, The Lind Partners, LLC

ImmuPharma plc to Report First Half, 2020 Results on Aug 20, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad